Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials

BACKGROUND: Laquinimod 0.6 mg is a once-daily, oral, disease-modifying therapy in development for the treatment of multiple sclerosis (MS) that was investigated in two double-blind, placebo-controlled, phase 3 trials: ALLEGRO and BRAVO. METHODS: Data from these studies were pooled to assess the safe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J MS Care
Main Authors: Sørensen, Per Soelberg, Comi, Giancarlo, Vollmer, Timothy L., Montalban, Xavier, Kappos, Ludwig, Dadon, Yuval, Gorfine, Tali, Margalit, Maya, Sasson, Nissim, Rubinchick, Svetlana, Knappertz, Volker
Formato: Artigo
Idioma:Inglês
Publicado em: The Consortium of Multiple Sclerosis Centers 2017
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5315319/
https://ncbi.nlm.nih.gov/pubmed/28243182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073.2015-024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados